Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Therapy Name | ADCT-601 |
| Synonyms | |
| Therapy Description |
ADCT-601 (BGB 601) is an antibody-drug conjugate (ADC) comprising an antibody targeting AXL linked to PL1601, which delivers the cytotoxic agent SG3199 to AXL-expressing tumor cells, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ADCT-601 | ADCT601|ADCT 601|BGB 601|BGB601|BGB-601 | AXL Antibody 5 | ADCT-601 (BGB 601) is an antibody-drug conjugate (ADC) comprising an antibody targeting AXL linked to PL1601, which delivers the cytotoxic agent SG3199 to AXL-expressing tumor cells, potentially leading to decreased tumor growth (Cancer Res July 1 2018 (78) (13 Supplement) 2792A). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL positive | pancreatic cancer | sensitive | ADCT-601 | Preclinical - Pdx | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive pancreatic cancer cell line in culture and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 35086955). | 35086955 |
| AXL positive | ovary adenocarcinoma | sensitive | ADCT-601 | Preclinical - Cell culture | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive ovarian adenocarcinoma cell line in culture (PMID: 35086955). | 35086955 |
| AXL positive | esophageal cancer | sensitive | ADCT-601 | Preclinical - Pdx | Actionable | In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive esophageal cancer cell line in culture and resulted in complete responses in 2/8, partial responses in 5/8, and tumor-free survival in 2/8 patient-derived xenograft (PDX) models (PMID: 35086955). | 35086955 |
| AXL positive | glioblastoma | sensitive | ADCT-601 | Preclinical - Cell culture | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive glioblastoma cell line in culture (PMID: 35086955). | 35086955 |
| AXL positive | lung adenocarcinoma | sensitive | ADCT-601 | Preclinical - Cell culture | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive lung adenocarcinoma cell line in culture (PMID: 35086955). | 35086955 |
| AXL positive | triple-receptor negative breast cancer | sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ADCT-601 treatment inhibited growth of an AXL-positive triple-negative breast cancer cell line in culture and resulted in complete responses in 4/10, partial responses in 5/10, and tumor-free survival in 4/10 cell line xenograft models (PMID: 35086955). | 35086955 |
| AXL positive | renal cell carcinoma | sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, treatment with ADCT-601 induced DNA interstrand crosslinking and inhibited growth of an AXL-positive renal cell carcinoma cell line in culture and at the highest tested dose resulted in a partial response in 1/8, complete responses in 7/8, and tumor-free survival in 6/8 cell line xenograft models (PMID: 35086955). | 35086955 |
| AXL positive | lung non-small cell carcinoma | sensitive | ADCT-601 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, ADCT-601 inhibited growth of an AXL-positive non-small cell lung cancer cell line in culture and inhibited tumor growth and increased survival in a cell line xenograft model (PMID: 35086955). | 35086955 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
| NCT05389462 | Phase I | ADCT-601 + Gemcitabine ADCT-601 | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors | Recruiting | USA | GBR | FRA | ESP | 0 |
CKB BOOST